You are here

Planet Biotechnology Incorporated

Company Information
Address
25571 CLAWITER RD
HAYWARD , CA 94545-2740
United States



Information

UEI: KTJKPBE2H5H3

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections

    Amount: $300,000.00

    Burkholderia pseudomallei (Bp) is the causative agent of melioidosis, a major cause of morbidity and septic death in tropical/subtropical regions worldwide. It is particularly virulent in diabetic pat ...

    STTRPhase I2023Department of Health and Human Services National Institutes of Health
  2. FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease

    Amount: $2,000,000.00

    Lyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sens ...

    SBIRPhase II2022Department of Health and Human Services National Institutes of Health
  3. Improving gene expression via Massively Parallel Synonymous Codon Variant Screening

    Amount: $298,634.00

    Our overall goal is to reduce to practice an innovative new method for empirically identifying the optimal codon usage for any gene where the intent is to maximize protein accumulation, in either hete ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  4. Recombinant Fc fusions for treatment of uropathogenic E. coli

    Amount: $486,870.00

    Urinary tract infections (UTIs) are among the most common bacterial infections, affecting 150 million people worldwide each year. In the USA, community-acquired UTIs account for about 11 million cases ...

    STTRPhase I2020Department of Health and Human Services National Institutes of Health
  5. FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease

    Amount: $444,684.00

    Lyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sens ...

    STTRPhase I2020Department of Health and Human Services National Institutes of Health
  6. An immunotherapeutic to prevent gonorrhea

    Amount: $1,727,108.00

    Antimicrobial resistance is a major public health problem worldwide. Neisseria gonorrhoeae (Ng), the causative agent of the sexually transmitted infection gonorrhea, has become multidrug-resistant and ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  7. An immunotherapeutic to prevent gonorrhea

    Amount: $300,000.00

    Antimicrobial resistance is a major public health problem worldwideNeisseria gonorrhoeaeNgthe causative agent of the sexually transmitted infection gonorrheahas become multidrug resistant and has achi ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  8. An immunoadhesin therapy for glioblastoma targeting CD97

    Amount: $263,999.00

    Effective treatment of glioblastomaGBMthe most common and most lethal human brain tumorrepresents one of the most formidable challenges in oncologyDespite the use of surgeryradiation therapy and chemo ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  9. A mucosally targeted MERS CoV vaccine produced in plants

    Amount: $236,488.00

    DESCRIPTION provided by applicant Middle East Respiratory Syndrome MERS coronavirus MERS CoV causes severe acute respiratory illness with a high fatality rate among reported cases MERS was fi ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  10. A novel anti gonorrhea immunotherapeutic

    Amount: $242,093.00

    Antimicrobial resistance is a major public health problem worldwide Neisseria gonorrhoeae Ng the causative agent of the sexually transmitted infection gonorrhea has become multidrug resistant and ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government